Medtronic PLC $MDT Shares Sold by Teacher Retirement System of Texas

Key Points

• Teacher Retirement System of Texas cut its stake in Medtronic by 39.6%, selling 195,350 shares in Q4 and leaving 297,593 shares valued at about $28.59 million.
• EVP Harry Skip Kiil sold 52,524 shares on Feb. 19 at an average price of $97.71 for roughly $5.13 million, reducing his ownership by 61.58%.
• Medtronic beat quarterly revenue and EPS estimates, set FY2026 guidance of 5.62–5.66 EPS, and is advancing strategic catalysts (CathWorks AI deal and early commercial use of the Stealth AXiS robotic platform) while paying a $0.71 quarterly dividend (3.4% yield).

Teacher Retirement System of Texas cut its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 39.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 297,593 shares of the medical technology company's stock after selling 195,350 shares during the period. Teacher Retirement System of Texas' holdings in Medtronic were worth $28,587,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Curbstone Financial Management Corp lifted its position in Medtronic by 1.8% during the fourth quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company's stock valued at $537,000 after purchasing an additional 100 shares during the period. Baker Tilly Wealth Management LLC lifted its position in Medtronic by 3.3% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company's stock valued at $309,000 after purchasing an additional 102 shares during the period. Riverbend Wealth Management LLC lifted its position in Medtronic by 3.2% during the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company's stock valued at $332,000 after purchasing an additional 107 shares during the period. Maseco LLP lifted its position in Medtronic by 32.1% during the fourth quarter. Maseco LLP now owns 444 shares of the medical technology company's stock valued at $43,000 after purchasing an additional 108 shares during the period. Finally, Holistic Financial Partners lifted its position in Medtronic by 3.0% during the third quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company's stock valued at $352,000 after purchasing an additional 109 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Completed CathWorks deal and new investment broaden Medtronic’s AI heart-care footprint (adds AI coronary diagnostics; also led a $100M investment in Pulnovo) — accelerates higher-margin, software-enabled offerings that can lift long-term growth. Read More.
• Positive Sentiment: Commercial progress: first surgeons have used the Stealth AXiS Autopilot surgical robotic platform — marks a tangible commercialization milestone for Medtronic’s robotics strategy and could support procedure volume and recurring revenue. Read More.
• Positive Sentiment: Investor interest in strategic moves — coverage noting a new GE HealthCare tie-up and Altaviva launch alongside M&A/launch activity has drawn attention to potential catalysts for re-rating if momentum continues. Read More.
• Neutral Sentiment: Analyst stance: Jefferies reiterated a Hold and says portfolio streamlining (including the diabetes spin-off) has benefits but is offset by a lower growth outlook and valuation compression — supports cautious investor positioning. Read More.
• Neutral Sentiment: UBS trimmed its price target to $90 from $104 and maintains a neutral rating — near-term analyst-driven cap on upside until execution or guidance surprises. Read More.
• Neutral Sentiment: Industry tailwinds: multiple market reports name Medtronic as a leading player in catheters, home/long-term care devices, and automated insulin-delivery systems — underscores TAM exposure but not immediate earnings impact. Read More.
• Neutral Sentiment: Corporate recognition: Medtronic’s CISO was honored at the HoustonCISO ORBIE Awards — positive PR but limited direct stock impact. Read More.
• Negative Sentiment: Share weakness and volatility: recent coverage highlights a notable YTD decline and short-term selloffs, which can pressure multiples and invite further analyst scrutiny if momentum doesn’t recover. Read More.
• Negative Sentiment: Recent daily dip: headlines note a larger-than-market intraday move downward in recent sessions — reinforcing near-term investor caution. Read More.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.26% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on MDT. Stifel Nicolaus decreased their target price on shares of Medtronic from $105.00 to $95.00 and set a "hold" rating for the company in a research report on Monday, April 6th. Wall Street Zen cut shares of Medtronic from a "buy" rating to a "hold" rating in a report on Saturday, April 11th. Citigroup decreased their price objective on shares of Medtronic from $117.00 to $110.00 and set a "buy" rating for the company in a research report on Tuesday, April 7th. Argus decreased their price objective on shares of Medtronic from $125.00 to $115.00 and set a "buy" rating for the company in a research report on Monday, April 6th. Finally, Robert W. Baird upped their price objective on shares of Medtronic from $92.00 to $93.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 15th. Fifteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $107.80.

Medtronic Trading Up 0.7%

Shares of Medtronic stock opened at $83.80 on Friday. The firm has a 50-day simple moving average of $90.10 and a two-hundred day simple moving average of $95.36. The company has a market cap of $107.59 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 2.16 and a beta of 0.75. Medtronic PLC has a fifty-two week low of $79.93 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were given a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.4%. Medtronic's dividend payout ratio (DPR) is 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.